Indigo Diabetes increased its total funding to $52.6m with a series B round backed by Ackermans & van Haaren.
Belgium-based diabetes management technology developer Indigo Diabetes yesterday obtained €38m ($44.5m) of series B capital from investors including diversified conglomerate Ackermans & van Haaren.
The round was led by Fund+ and also includedmulti-university venture fund Qbic II and Imec.xpand, the fund of nanoelectronics research institute Imec.
Capricorn Digital Growth Fund, private investor Titan Baratto and unnamed investors from Indigo’s series A round filled out the consortium.
Spun out of Ghent University in 2016, Indigo Diabetes has devised a compact, needle-free…